Exonics Therapeutics

Recent Finacing

Series A

Recent Raise

$40M

Exonics Therapeutics develops SingleCut CRISPR/Cas9 AAV-delivered, one-time gene-editing therapies to correct exon mutations that restore dystrophin production in Duchenne muscular dystrophy; technology licensed from UT Southwestern.

Founded 2016

Massachusetts, United States

11-50

Private

exonicstx.com

Highlights

Focus Areas

Biopharma

Biotechnology

Medical Device

Therapeutics

Recent Investors

Financials

$45M

Total Raised

2

Funding rounds

2

Investors